305 related articles for article (PubMed ID: 21376994)
21. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Lane BR; Zippe CD; Abouassaly R; Schoenfield L; Magi-Galluzzi C; Jones JS
J Urol; 2008 May; 179(5):1746-50; discussion 1750. PubMed ID: 18343412
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
23. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
Johnson L
Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
[No Abstract] [Full Text] [Related]
24. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
[TBL] [Abstract][Full Text] [Related]
25. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
Roddam AW; Hamdy FC; Allen NE; Price CP;
BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
[TBL] [Abstract][Full Text] [Related]
26. [Detection of prostate cancer: yes or no?].
Van Cangh PJ
Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
[No Abstract] [Full Text] [Related]
27. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
Miocinovic R; Jones JS; Pujara AC; Klein EA; Stephenson AJ
Urology; 2011 Apr; 77(4):980-4. PubMed ID: 21256549
[TBL] [Abstract][Full Text] [Related]
28. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
29. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
Hegarty JM; Wallace M; Comber H
Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
[TBL] [Abstract][Full Text] [Related]
30. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer: who and how often?
Schwartz K; Deschere B; Xu J
J Fam Pract; 2005 Jul; 54(7):586-96. PubMed ID: 16009085
[TBL] [Abstract][Full Text] [Related]
32. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
33. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
34. Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
Autorino R; Perdonà S; Di Lorenzo G
Urology; 2010 Nov; 76(5):1076; author reply 1076-7. PubMed ID: 21056255
[No Abstract] [Full Text] [Related]
35. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
Stanislaus P; Seitz M
Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
[No Abstract] [Full Text] [Related]
36. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
37. Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer.
Resnick MJ; Lee DJ; Magerfleisch L; Vanarsdalen KN; Tomaszewski JE; Wein AJ; Malkowicz SB; Guzzo TJ
Urology; 2011 Mar; 77(3):548-52. PubMed ID: 21215436
[TBL] [Abstract][Full Text] [Related]
38. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
Markun S
Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
[No Abstract] [Full Text] [Related]
39. [Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].
van der Kwast TH; Hoedemaeker RF; Schröder FH
Ned Tijdschr Geneeskd; 2005 Apr; 149(18):972-6. PubMed ID: 15903037
[TBL] [Abstract][Full Text] [Related]
40. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]